Teva- Pharmaceutical Industries Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $17.3B+4.7% YoYTTM through 30 Jun 2026
Net Income $706MTTM through 30 Jun 2026
Free Cash Flow $1.3BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 52.5% |
| EBITDA Margin | 15.0% |
| Operating Margin | 9.3% |
| Net Margin | 4.1% |
Returns
9.1%ROE
1.8%ROA
8.2%ROIC
Balance Sheet Health
Debt / Equity0.58x
Current Ratio0.88x
Net Debt$845M
Cash & Equivalents$3.7B
Quality Metrics
Altman Z-Score0.88
Piotroski F-Score6 / 9
FCF Margin7.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $17.3B
Diluted EPS$0.60TTMFY2025: $1.21
Dividend
$0.85Per share, FY20172.15%Yield1 yrsStreak
Capital Allocation
Capex Intensity3.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| United States | $9.2B | +14.3% | View detailsCommencing January 1, 2026, Anda is no longer reported under the United States segment and is shifted to Other Activities to allow the U.S. segment to focus on its biopharmaceutical business and innovative growth engines. |
| Europe | $5B | -1.0% | View detailsTeva continues to optimize its European product portfolio and generic business to improve margins. |
| International Markets | $2.2B | -12.0% | View detailsFocusing on branded generics and innovative medicines in CNS, respiratory, and oncology across more than 35 countries. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.